Literature DB >> 12558457

Vaccines against drugs of abuse: a viable treatment option?

Kathleen M Kantak1.   

Abstract

Drug addiction is a chronically relapsing brain disorder. There is an urgent need for new treatment options for this disease because the relapse rate among drug abusers seeking treatment is quite high. During the past decade, many groups have explored the feasibility of using vaccines directed against drugs of abuse as a means of eliminating illicit drug use as well as drug overdose and neurotoxicity. Vaccines work by inducing drug-specific antibodies in the bloodstream that bind to the drug of abuse and prevent its entry into the brain. The majority of work in this area has been conducted with vaccines and antibodies directed against cocaine and nicotine. On the basis of preclinical work, vaccines for cocaine and nicotine are now in clinical trials because they can offer long-term protection with minimal treatment compliance. In addition, vaccines and antibodies for phencyclidine, methamphetamine and heroin abuse are currently under development. An underlying theme in this research is the need for high concentrations of circulating drug-specific antibodies to reduce drug-seeking and drug-taking behaviour when the drug is repeatedly available, especially in high doses. Although vaccines against drugs of abuse may become a viable treatment option, there are several drawbacks that need to be considered. These include: a lack of protection against a structurally dissimilar drug that produces the same effects as the drug of choice;a lack of an effect on drug craving that predisposes an addict to relapse; and tremendous individual variability in antibody formation. Forced or coerced vaccination is not likely to work from a scientific perspective, and also carries serious legal and ethical concerns. All things considered, vaccination against a drug of abuse is likely to work best with individuals who are highly motivated to quit using drugs altogether and as part of a comprehensive treatment programme. As such, the medical treatment of drug abuse will not be radically different from treatment of other chronic diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12558457     DOI: 10.2165/00003495-200363040-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  52 in total

1.  Anticocaine catalytic antibodies have no affinity for RTI compounds: implications for treatment.

Authors:  M J Kuhar; F I Carroll; N Bharat; D W Landry
Journal:  Synapse       Date:  2001-08       Impact factor: 2.562

2.  Arterial and venous cocaine plasma concentrations in humans: relationship to route of administration, cardiovascular effects and subjective effects.

Authors:  S M Evans; E J Cone; J E Henningfield
Journal:  J Pharmacol Exp Ther       Date:  1996-12       Impact factor: 4.030

3.  Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats.

Authors:  J W Proksch; W B Gentry; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

4.  Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.

Authors:  J L Valentine; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

5.  An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis.

Authors:  S Isomura; P Wirsching; K D Janda
Journal:  J Org Chem       Date:  2001-06-15       Impact factor: 4.354

6.  Active cocaine immunization attenuates the discriminative properties of cocaine.

Authors:  M W Johnson; R H Ettinger
Journal:  Exp Clin Psychopharmacol       Date:  2000-05       Impact factor: 3.157

7.  Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion.

Authors:  Y Tuncok; Y Hieda; D E Keyler; S Brown; S Ennifar; A Fattom; P R Pentel
Journal:  Exp Clin Psychopharmacol       Date:  2001-05       Impact factor: 3.157

8.  Cocaethylene formation in rat, dog, and human hepatic microsomes.

Authors:  N Song; R B Parker; S C Laizure
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

9.  Cocaine craving: an evaluation across treatment phases.

Authors:  P S Bordnick; J M Schmitz
Journal:  J Subst Abuse       Date:  1998

10.  A second-generation vaccine protects against the psychoactive effects of cocaine.

Authors:  M R Carrera; J A Ashley; P Wirsching; G F Koob; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  12 in total

1.  Substance abuse prevention: practical strategies for psychiatrists in the 21st century.

Authors:  Peter Selby; Franco J Vaccarino
Journal:  World Psychiatry       Date:  2005-02       Impact factor: 49.548

2.  Withdrawal from fixed-dose injection of methamphetamine decreases cerebral levels of 3-methoxy-4-hydroxyphenylglycol and induces the expression of anxiety-related behavior in mice.

Authors:  Nobue Kitanaka; Junichi Kitanaka; Tomohiro Tatsuta; Koh-ichi Tanaka; Kaname Watabe; Nobuyoshi Nishiyama; Yoshio Morita; Motohiko Takemura
Journal:  Neurochem Res       Date:  2010-02-11       Impact factor: 3.996

3.  A molecular model for cocaine binding by the immunotherapeutic human/mouse chimeric monoclonal antibody 2E2.

Authors:  Michael Lape; Stefan Paula; William J Ball
Journal:  Eur J Med Chem       Date:  2010-02-06       Impact factor: 6.514

4.  Ethical Implications in Vaccine Pharmacotherapy for Treatment and Prevention of Drug of Abuse Dependence.

Authors:  Anna Carfora; Paola Cassandro; Alessandro Feola; Francesco La Sala; Raffaella Petrella; Renata Borriello
Journal:  J Bioeth Inq       Date:  2018-01-19       Impact factor: 1.352

5.  Impact of distinct chemical structures for the development of a methamphetamine vaccine.

Authors:  Amira Y Moreno; Alexander V Mayorov; Kim D Janda
Journal:  J Am Chem Soc       Date:  2011-04-07       Impact factor: 15.419

Review 6.  Controversies in translational research: drug self-administration.

Authors:  Margaret Haney; Roger Spealman
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

Review 7.  Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence.

Authors:  Amira Y Moreno; Kim D Janda
Journal:  Pharmacol Biochem Behav       Date:  2009-04       Impact factor: 3.533

8.  Role of the orbitofrontal cortex and dorsal striatum in regulating the dose-related effects of self-administered cocaine.

Authors:  Kathleen M Kantak; Yasmin Mashhoon; David N Silverman; Amy C Janes; Claudia M Goodrich
Journal:  Behav Brain Res       Date:  2009-02-11       Impact factor: 3.332

9.  Modification of Monoaminergic Activity by MAO Inhibitors Influences Methamphetamine Actions.

Authors:  Junichi Kitanaka; Nobue Kitanaka; Motohiko Takemura
Journal:  Drug Target Insights       Date:  2006-11-09

10.  Pharmacokinetics of α-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an α-Pyrrolidinovalerophenone Vaccine.

Authors:  Samantha McClenahan; Melinda Gunnell; Michael Owens
Journal:  J Pharm Pharm Sci       Date:  2021       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.